オメガ3処方薬市場レポート：2030年までの動向、予測、競合分析

オメガ3処方薬の動向と予測

世界のオメガ3処方薬市場は、2024年から2030年までのCAGRが8.5％で、2030年までに推定48億米ドルに達すると予想されます。この市場の主な促進要因は、高トリグリセリド血症、肥満、心血管疾患（CVD）の割合の上昇、コレステロール値維持に対する意識の高まりであり、市場のプレーヤーは、関連する医療問題を治療するための革新的な医薬品の創出に注力しています。世界のオメガ3処方薬市場の将来は、高トリグリセリド血症、高コレステロール血症、炎症性腸疾患、関節リウマチ、精神疾患、神経発達障害市場における機会によって有望視されています。

オメガ3処方薬市場の洞察

Lucintelは、Vascepaが広く受け入れられているため、予測期間中、Vascepaが最大セグメントであり続けると予測しています。

北米は、心臓関連疾患に対する地域的な不安の高まりにより、予測期間中も最大地域であり続けると予想されます。

本レポートでは、以下の11の主要な質問に回答している：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のオメガ3処方薬市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のオメガ3処方薬市場動向（2018～2023年）と予測（2024～2030年）
• 医薬品別の世界のオメガ3処方薬市場
  • Vascepa
  • Lovaza
  • その他
• 流通チャネル別の世界のオメガ3処方薬市場
  • 病院薬局
  • 小売薬局
  • オンライン薬局
• 用途別の世界のオメガ3処方薬市場
  • 高トリグリセリド血症
  • 高コレステロール
  • 炎症性腸疾患
  • 関節リウマチ
  • 精神疾患
  • 神経発達障害
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界のオメガ3処方薬市場
• 北米のオメガ3処方薬市場
• 欧州のオメガ3処方薬市場
• アジア太平洋のオメガ3処方薬市場
• その他地域のオメガ3処方薬市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 医薬品別の世界のオメガ3処方薬市場の成長機会
  • 流通チャネル別の世界のオメガ3処方薬市場の成長機会
  • 用途別の世界のオメガ3処方薬市場の成長機会
  • 地域別の世界のオメガ3処方薬市場の成長機会
• 世界のオメガ3処方薬市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のオメガ3処方薬市場の生産能力の拡大
  • 世界のオメガ3処方薬市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Abbott
• Amarin Pharmaceuticals
• GSK
• Natrapharm
• Viatris
• Grupo Ferrer Internacional
• Camber Pharmaceuticals
• Dr. Reddy's Laboratories
• Zydus
• Hikma Pharmaceuticals

Omega 3 Prescription Drug Trends and Forecast

The future of the global omega 3 prescription drug market looks promising with opportunities in the hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders markets. The global omega 3 prescription drug market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 8.5% from 2024 to 2030. The major drivers for this market are rising rates of hypertriglyceridemia, obesity, and cardiovascular diseases (CVDs), growing awareness for maintaining cholesterol levels, and players in the market are concentrating on creating innovative medications to treat linked medical issues.

A more than 150-page report is developed to help in your business decisions.

Omega 3 Prescription Drug by Segment

The study includes a forecast for the global omega 3 prescription drug by drug, distribution channel, application, and region.

Omega 3 Prescription Drug Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

• Vascepa
• Lovaza
• Others

Omega 3 Prescription Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Omega 3 Prescription Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Hypertriglyceridemia
• High Cholesterol
• Inflammatory Bowel Disease
• Rheumatoid Arthritis
• Mental Health Conditions
• Neurodevelopmental Disorders
• Others

Omega 3 Prescription Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Omega 3 Prescription Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies omega 3 prescription drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the omega 3 prescription drug companies profiled in this report include-

• Abbott
• Amarin Pharmaceuticals
• GSK
• Natrapharm
• Viatris
• Grupo Ferrer Internacional
• Camber Pharmaceuticals
• Dr. Reddy's Laboratories
• Zydus
• Hikma Pharmaceuticals

Omega 3 Prescription Drug Market Insights

Lucintel forecasts that vascepa will remain the largest segment over the forecast period due to widespread acceptance of vascepa.

North America will remain the largest region over the forecast period due to increasing regional apprehension regarding heart-related conditions.

Features of the Global Omega 3 Prescription Drug Market

Market Size Estimates: Omega 3 prescription drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Omega 3 prescription drug market size by drug, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Omega 3 prescription drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug, distribution channel, application, and regions for the omega 3 prescription drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the omega 3 prescription drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the omega 3 prescription drug market size?

Answer: The global omega 3 prescription drug market is expected to reach an estimated $4.8 billion by 2030.

Q2. What is the growth forecast for omega 3 prescription drug market?

Answer: The global omega 3 prescription drug market is expected to grow with a CAGR of 8.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the omega 3 prescription drug market?

Answer: The major drivers for this market are rising rates of hypertriglyceridemia, obesity, and cardiovascular diseases (CVDs), growing awareness for maintaining cholesterol levels, and players in the market are concentrating on creating innovative medications to treat linked medical issues.

Q4. What are the major segments for omega 3 prescription drug market?

Answer: The future of the global omega 3 prescription drug market looks promising with opportunities in the hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders markets.

Q5. Who are the key omega 3 prescription drug market companies?

Answer: Some of the key omega 3 prescription drug companies are as follows:

• Abbott
• Amarin Pharmaceuticals
• GSK
• Natrapharm
• Viatris
• Grupo Ferrer Internacional
• Camber Pharmaceuticals
• Dr. Reddy's Laboratories
• Zydus
• Hikma Pharmaceuticals

Q6. Which omega 3 prescription drug market segment will be the largest in future?

Answer: Lucintel forecasts that vascepa will remain the largest segment over the forecast period due to widespread acceptance of vascepa.

Q7. In omega 3 prescription drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing regional apprehension regarding heart-related conditions.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the omega 3 prescription drug market by drug (vascepa, lovaza, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), application (hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Omega 3 Prescription Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Omega 3 Prescription Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Omega 3 Prescription Drug Market by Drug
  • 3.3.1: Vascepa
  • 3.3.2: Lovaza
  • 3.3.3: Others
• 3.4: Global Omega 3 Prescription Drug Market by Distribution Channel
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Online Pharmacy
• 3.5: Global Omega 3 Prescription Drug Market by Application
  • 3.5.1: Hypertriglyceridemia
  • 3.5.2: High Cholesterol
  • 3.5.3: Inflammatory Bowel Disease
  • 3.5.4: Rheumatoid Arthritis
  • 3.5.5: Mental Health Conditions
  • 3.5.6: Neurodevelopmental Disorders
  • 3.5.7: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Omega 3 Prescription Drug Market by Region
• 4.2: North American Omega 3 Prescription Drug Market
  • 4.2.2: North American Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
• 4.3: European Omega 3 Prescription Drug Market
  • 4.3.1: European Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
  • 4.3.2: European Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
• 4.4: APAC Omega 3 Prescription Drug Market
  • 4.4.1: APAC Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
  • 4.4.2: APAC Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
• 4.5: ROW Omega 3 Prescription Drug Market
  • 4.5.1: ROW Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
  • 4.5.2: ROW Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Drug
  • 6.1.2: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Application
  • 6.1.4: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Region
• 6.2: Emerging Trends in the Global Omega 3 Prescription Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Omega 3 Prescription Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Omega 3 Prescription Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott
• 7.2: Amarin Pharmaceuticals
• 7.3: GSK
• 7.4: Natrapharm
• 7.5: Viatris
• 7.6: Grupo Ferrer Internacional
• 7.7: Camber Pharmaceuticals
• 7.8: Dr. Reddy's Laboratories
• 7.9: Zydus
• 7.10: Hikma Pharmaceuticals